1Walters S,Porter C,Brophy P.Dialysis and pediatric acute kidney injury:choice of renal support modality[J].Pediatric Nephrology,2009,24(1):37-48.
2Homer C,Schuster S,Plachky J,et al.Hemofiltration and immune response in severe sepsis[J].Journal of Surgical Research,2007,142(1):59-65.
3Nakada T,Oda S,Matsuda K,et al.Continuous hemodiafiltration with PMMA hemofilter in the treatment of patients with septic shock[J].Critical Care Medicine,2008,14(2):257-266.
4Germann P.Cytokine patterns in patients who undergo hemofiltration for treatment of multiple organ failure[J].World Journal of Surgery,2008,37(3):443-448.
5Nakae,Joannidis M.Continuous renal replacement therapy in sepsis and multisystem organ failure[J].Kidney Int,2009,20(2):160-164.
6Sykora R,Chvojka J,Krouzecky A,et al.Effects of continuous hemofiltration on organ perfusion,energy metabolism,oxidative stress,endothelial dysfunction and inflammation[J].Critical Care Volume,2009,14(2) 1273-281.
7Chen ZH,Liu ZH,Yu C,et al.Endothelial dysfunction in patients with severe acute pancreatitis:improved by continuous blood purification therapy[J].Int J ArtifOrgans,2007,22(4):393-400.
8Lekkou A,Karakantza M,Mouzaki A,et al.Cytokine production and monocyte HLADR expression as predictors of outcome for patients with community-acquired severe infections[J].Clin Diagn Lab Immunol,2004,17(1):161-167.
10Korevaar JC,van Manen JG,Dekker FW,et al.Effect of an increase in C-reactive protein level during a hemodialysis session on mortality[J].J Am Soc Nephrol,2004,15(10):2916-2922.
2Marshall JB.Acute pancreatitis.A review with an emphasis on new developments.Arch Intern Med,1993,153(10):1185-1198.
3Fisher CJ Jr,Slotman GJ,Opal SM,et al.Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome:a randomized,open-label,placebo-controlled multicenter trial.Crit Care Med,1994,22:12-21.
4Eskandari MK,Bolgos G,Miller C,et al.Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia.J Immunol,1992,148:2724-2730.
5AL SM,Cross,Jhung JW,et al.Potential hazards of combination immunotherapy in the treatment of experimental septic shock.J Infect Dis,1996,173:1415-1421.
6Satoshi O,Hironori T,Atsushi M,et al.Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber.Am J Surg,2004,188(2):150-156.
7Yizhi Peng,Zhiqiang Yuan,Hongbin Li.Removal of inflammatory cytokines and endotoxin by veno-venous continuous renal replacement therapy for burned patients with sepsis.Burns,2005,31:623-628.
8A.S.De Vriese,R.C.Vanholder,M.Pascual,et al.Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? Intensive Care Med,1999,25:903-910.
9Heinz GU,Nter Sieberth and HORST P.K,et al.Is cytokine removal by continuous hemofiltration feasible? Kidney Int,1999,56,Suppl(72):S79-83.
10Mayer J,Rau B,Gansauge F,et al.Inflammatory mediators in human acute pancreatitis:clinical and pathophysiological implications.Gut,2000,47:546-552.
